On the filings, BioMarin (BMRN) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it BUY.
Jazz's rare-disease engine still threw off $1.36B of cash on growing sales, but a GAAP net loss and $5.4B of debt keep this a show-me story.
Rare-disease biotech with 13% revenue growth led by Voxzogo and a pristine balance sheet, now levering up for the $4.8B Amicus deal.
| Metric | JAZZ | BMRN |
|---|---|---|
| Fundamentals score | 37 | 67 |
| Revenue growth (YoY) | +4.9% | +12.9% |
| Net income growth (YoY) | -163.6% | -18.3% |
| Net margin | -8.3% | 10.8% |
| Return on equity | -8.2% | 5.7% |
| ROIC (est.) | -3.5% | 5.3% |
| Liabilities / Equity | — | 0.25 |
| Piotroski F-score | 4 / 9 | 4 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:46 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:48 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.